Drug intelligence / Profile preview

BRG0001

Development stage: Preclinical
Lead developer: Berg

Overview

BRG0001 is a preclinical drug candidate being developed by BPGbio (formerly Berg Health) for the treatment of conditions involving pathological angiogenesis. It was identified using BPGbio's Interrogative Biology® platform, which utilizes AI and multi-omics data to map disease biology. While specific molecular targets and modalities have not been publicly disclosed, the program is categorized under the company's drug discovery pipeline as an anti-angiogenic agent, likely intended for oncology or other vascular-related indications.

Beyond the preview

Go deeper on BRG0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRG0001.

Explore the full profile